Why this isn't a straightforward head-to-head

The question patients usually arrive with — "which is better?" — turns out to be the wrong question. ChondroFiller and Arthrosamid do not compete for the same problem. ChondroFiller targets a localised patch of damaged articular cartilage; Arthrosamid integrates permanently into the synovial membrane to cushion and calm a joint affected by more widespread osteoarthritis. Because they act on anatomically different tissues, the real clinical decision pivots on one distinction: focal, single-compartment cartilage damage versus diffuse, multi-compartment osteoarthritis — not on which product scores higher in some abstract ranking.

No published head-to-head randomised controlled trial has compared the two directly, so a straight ranking is not possible. Meaningful comparison has to be built from understanding what each product is designed to do — and whether a patient's knee matches that design.

In practical terms, both are delivered as outpatient, image-guided injections under ultrasound. The clinical experience from the patient's perspective is broadly similar; the biology is not. The sections that follow examine each product's mechanism, the evidence behind it, and the patient profile it suits — because the right answer depends almost entirely on the pattern of damage inside a particular knee.

What ChondroFiller does inside a focal cartilage defect

Injected under ultrasound guidance during an outpatient appointment, ChondroFiller arrives at the defect site as a liquid. Within three to five minutes of contact with body heat, it undergoes an irreversible phase change, setting into a stable gel that fills the focal lesion. Nothing is implanted surgically; the material self-positions as it transitions.

ChondroFiller is an acid-extracted, type I collagen gel — acellular, meaning it contains no donor cells. It is CE-marked as a Class III medical device. The gel's role is structural and biological: it acts as a temporary scaffolding that recruits the patient's own progenitor cells from the surrounding synovium and the underlying subchondral bone. That process — acellular matrix-induced chondrogenesis — means the scaffold draws in the body's own repair cells rather than delivering external ones. An ex vivo model confirmed a 2.4-fold increase in cellular DNA content within the scaffold by day 14, consistent with active cell recruitment and matrix formation.

The scaffold persists for roughly six to twenty-four months while the body lays down new cartilage matrix within and around it, then biodegrades without leaving permanent foreign material in the joint. For patients thinking ahead to possible future treatment, including knee replacement, this matters: there is no residual implant to account for later.

ChondroFiller, in short, supports the body's own repair processes at a discrete, mappable focal lesion. It is not a permanent filler and does not claim to restore a worn joint in its entirety.

What Arthrosamid does in a diffuse OA knee

Arthrosamid is composed of 97.5% water bound within a 2.5% polyacrylamide polymer network — a stable, non-biodegradable hydrogel that, once injected into the knee under ultrasound guidance, settles into and integrates permanently with the synovial membrane lining the joint capsule. Unlike ChondroFiller, it does not degrade over time; the material stays where it is placed.

Its therapeutic role is mechanical and anti-inflammatory rather than structural. By becoming part of the synovial lining, the hydrogel cushions the whole joint environment and appears to reduce intra-articular inflammation across all compartments simultaneously. This whole-joint effect is what makes it appropriate for diffuse knee osteoarthritis — KL grades II to IV — where there is no single discrete lesion to target but a broadly degraded joint environment that needs sustained modulation.

Permanence is the clinically significant factor that distinguishes Arthrosamid from any biodegradable product. Because the hydrogel integrates into the synovium and remains there indefinitely, this needs to be part of any conversation about future treatment planning, including total knee replacement. That is not a condemnation — the same permanence may underpin its durability as a pain and function treatment — but it is information that should be weighed before the injection, not after.

Arthrosamid does not recruit repair cells, does not produce new cartilage matrix, and is not designed to. It is a cushioning hydrogel, suited to a different tissue and a different pattern of disease from the focal cartilage defects that ChondroFiller addresses.

What the clinical evidence shows for each

The published figures for each product are specific to the patient group it was designed for — comparing them directly would be like comparing a bone graft to a splint.

ChondroFiller in focal cartilage lesions

Data from more than 19,000 treated cases show a typical improvement of roughly 30 points on the 0–100 IKDC functional score in knee patients. MRI-based MOCART regeneration scores — which grade how completely a defect has filled with new tissue — range from 70 to 87 in published series. A small multicentre randomised controlled study (13 ChondroFiller patients, 10 treated with microfracture) found statistically significant IKDC gains at 3, 6, and 12 months in the ChondroFiller group, with no adverse events recorded. The reported complaint rate across the wider clinical database sits at approximately 0.06%.

One practical caveat: a 2024 biomechanical study found that the freshly applied gel did not protect opposing cartilage surfaces from load-induced damage in its early state. Weight-bearing should be delayed after the procedure until the scaffold has stabilised — something patients should be clear on before they leave the clinic.

Arthrosamid in diffuse knee OA

A five-year extension of the original RCT (58 completers from 119 treated) showed a sustained WOMAC pain improvement of −16.2 points at year five — on a scale where larger negative numbers mean less pain. Gains held across all WOMAC domains and patient global assessment throughout, with no device-related adverse events in years one to five.

A separate 24-month real-world cohort of 314 knees found that older, non-diabetic patients with lower KL-grade OA were most likely to reach a meaningful clinical improvement threshold. Within two years, 15.6% of patients required total knee replacement — those were disproportionately the higher-grade OA cases, which points to where the treatment is less likely to hold. A comparative study against hyaluronic acid and corticosteroid found that both of those had returned to near-baseline pain scores by 12 months; Arthrosamid remained stable at that point.

Which patients suit ChondroFiller and which suit Arthrosamid

Sorting patients into the right column comes down to one anatomical question: is there a mappable focal lesion in an otherwise serviceable joint, or is the damage diffuse across the whole joint environment?

Patients more likely to benefit from ChondroFiller

ChondroFiller is best matched to patients with an isolated Grade III or IV cartilage loss confined to a single compartment, where the surrounding cartilage borders are largely intact. The scaffold needs good-quality tissue alongside it to contain the gel and support cell migration inward. Patients should also be able to follow post-injection weight-bearing guidance — the 2024 biomechanical data discussed earlier make clear that early loading before the scaffold stabilises creates a risk to the opposing cartilage surface.

Pre-existing diffuse or multi-compartment OA is the strongest contraindication. Hip data involving ChondroFiller gel showed that patients with Tönnis grade 2–3 OA — the equivalent of advanced diffuse disease — had consistently poor results at three-to-five year follow-up, while those with isolated lesions did well. The same principle applies in the knee: the scaffold is a precision repair tool, not a whole-joint treatment.

Patients more likely to benefit from Arthrosamid

Arthrosamid suits patients with diffuse knee osteoarthritis across one or more compartments — the very pattern that falls outside ChondroFiller's scope. As the cohort and RCT evidence in the previous section showed, lower Kellgren–Lawrence grade at the time of treatment is associated with more durable outcomes; higher-grade OA carries a greater risk of progressing to knee replacement within two years regardless of hydrogel treatment.

The permanent synovial integration that underpins Arthrosamid's durability is also the factor that warrants a careful conversation for anyone who may need total knee replacement in the future. It does not preclude surgery, but it is part of the planning discussion.

Where pathologies overlap

Occasionally a joint presents with both a focal cartilage defect and a background of diffuse OA — theoretically, a case where each product might address a different target. Treating both pathologies with the appropriate tool in the same joint is conceptually logical, but no clinical trial evidence exists for this combined approach. The decision would need to be made on individual clinical grounds, with full patient awareness that the combination is outside the published evidence base.

Accessing either treatment at MSK Doctors

Neither procedure involves hospital admission or general anaesthetic. An appointment at MSK Doctors begins with a consultant assessment, then moves to image-guided placement in the same outpatient setting — typically at the Regeneration Hub in Sleaford (NG34) or the Grantham centre (NG31). Patients do not need a GP referral, and there are no NHS-style waiting lists.

Before any treatment decision is finalised, pre-procedure imaging — a diagnostic MRI alongside weight-bearing X-rays — is used to map the extent of cartilage damage precisely. That imaging is what determines whether the pathology is focal and contained or diffuse across the compartment, which in turn confirms which product is clinically appropriate. The article's central question, in other words, is answered by your scans rather than by preference.

Both ChondroFiller and Arthrosamid are self-funded private treatments; guide costs start from approximately £3,000. Neither is currently NHS-commissioned. London-based patients can access the same clinical pathways through the London Cartilage Clinic, the MSK Doctors London arm.

For most patients, the clinical decision reduces to a single anatomical distinction — focal lesion or diffuse joint disease. Appointments can be booked directly at mskdoctors.com, without a referral.

1. [1] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759